What is the common examiner trap about Science & Tech in UPSC exams?

Examiners may confuse vepdegestrant with bavdegalutamide (the first PROTAC to enter human trials in 2019, for prostate cancer). Also, they might incorrectly state that PROTACs inhibit proteins like traditional drugs, when they actually degrade them. Another trap: claiming it is approved for all breast cancers, but it is specifically for ESR1-mutated, ER+/HER2- advanced cases after prior therapy.

What should UPSC aspirants remember about Science & Tech for Prelims?

1. Target this Drug: Vepdegestrant (first PROTAC approved by FDA) 2. Target this Date: May 1, 2026 (FDA approval date) 3. Target this Technology: PROTAC (Proteolysis Targeting Chimera) - catalytic protein degradation 4. Target this Cancer: ESR1-mutated, ER-positive, HER2-negative advanced breast cancer

Science & TechnologyHealth

Take AI Challenge ▸

News 0 of 21

FDA Approves Vepdegestrant: First PROTAC Drug for Advanced Breast Cancer (May 2026)

Q: Which companies jointly developed the drug vepdegestrant?

Arvinas & Pfizer, According to the article, vepdegestrant was developed by Arvinas and Pfizer. Arvinas is a US-based biotechnology company that pioneered PROTAC technology, and Pfizer collaborated to bring the drug to market.

Q: Consider the following statements regarding PROTAC technology: 1. PROTACs act as catalysts, degrading target proteins while themselves remaining intact. 2. The first FDA-approved PROTAC drug vepdegestrant targets the estrogen receptor for degradation. 3. PROTACs are small molecules that always have better oral bioavailability than traditional drugs. Which of the statements given above is/are correct?

Both 1 and 2, Statement 1 is correct: PROTACs are catalytic; after triggering degradation, they detach and can degrade another target. Statement 2 is correct: vepdegestrant degrades the estrogen receptor. Statement 3 is incorrect: PROTACs are larger and more complex, often leading to poorer oral bioavailability compared to traditional small-molecule drugs, as mentioned in the article.

Q: In the Phase 3 trial for vepdegestrant, what was the median progression-free survival in patients with ESR1-mutated tumours treated with vepdegestrant?

5 months, The article states that among 270 patients with ESR1-mutated tumours, the median progression-free survival was 5 months for vepdegestrant versus 2.1 months for fulvestrant. Option A is the value for fulvestrant, C and D are distractors not mentioned in the article.

Q: Why is the FDA approval of vepdegestrant considered a major shift in cancer therapy?

It is the first approved drug based on PROTAC technology, representing a new therapeutic modality of targeted protein degradation., The article highlights that vepdegestrant is the world's first FDA-approved PROTAC drug. Unlike traditional inhibitors, PROTACs degrade target proteins catalytically, offering a novel way to tackle previously 'undruggable' proteins and overcome resistance. Options A, C, and D are overgeneralizations not supported by the article.

Science & TechHIGH

Target:UPSC GS-IIIMPSCTeachingPrelims HighMains High

07 Jul 2026

~2 min

Source: The Hindu

Key Data:FDA approval May 1, 2026PROTAC technologyESR1-mutatedER-positive, HER2-negativePhase 3 trial 624 patientsPFS 5 months vs 2.1 months

Bodies:U.S. Food and Drug Administration (FDA)ArvinasPfizer

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.FDA approved vepdegestrant (Arvinas/Pfizer) on May 1, 2026, for a specific subset of advanced breast cancer.

2.It is the first FDA-approved drug using PROTAC (Proteolysis Targeting Chimera) technology, which catalytically degrades proteins.

3.Phase 3 trial (624 patients) showed vepdegestrant improved median progression-free survival to 5 months vs 2.1 months for fulvestrant in ESR1-mutated patients.

The Big Picture

Prelims · HighMains · High

The U.S. FDA approved vepdegestrant on May 1, 2026, for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer. It is the world's first approved drug based on PROTAC technology—a catalytic mechanism that degrades target proteins instead of inhibiting them. This marks a paradigm shift in cancer therapy with potential for targeting previously 'undruggable' proteins, making it a high-yield topic for Science & Technology in UPSC and other exams.

Exam Lens

Quick Exam Facts From News

Drug NameVepdegestrant

Approval DateMay 1, 2026 (by U.S. FDA)

TechnologyPROTAC (Proteolysis Targeting Chimera)

Target CancerESR1-mutated, ER-positive, HER2-negative advanced breast cancer

DeveloperArvinas & Pfizer

Phase 3 Trial Size624 patients

Progression-Free Survival (ESR1-mutated)5 months (vepdegestrant) vs 2.1 months (fulvestrant)

RouteOral once daily (vs intramuscular injection for fulvestrant)

First PROTAC in Human Trials (2019)Bavdegalutamide (prostate cancer)

1-Minute Revision

›Drug Name: Vepdegestrant
›Approval Date: May 1, 2026 (by U.S. FDA)
›Target this Drug: Vepdegestrant (first PROTAC approved by FDA)
›Target this Date: May 1, 2026 (FDA approval date)
›Target this Technology: PROTAC (Proteolysis Targeting Chimera) - catalytic protein degradation
›Target this Cancer: ESR1-mutated, ER-positive, HER2-negative advanced breast cancer

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

🧬

First PROTAC Approval

FDA approved vepdegestrant, the first drug using targeted protein degradation (PROTAC), for advanced breast cancer.

🔬

Clinical Breakthrough

Phase 3 trial showed superior progression-free survival over standard therapy (fulvestrant) in ESR1-mutated patients.

💊

New Therapeutic Paradigm

PROTACs degrade proteins catalytically, enabling lower doses and targeting proteins previously considered undruggable.

Detailed Analysis & Strategic Depth

Context / Background

Conventional cancer drugs work by binding to and inhibiting the function of a target protein. However, many proteins (like transcription factors) lack suitable binding pockets, making them 'undruggable'. PROTAC technology, first demonstrated in 2001 by Yale and Caltech, hijacks the cell's own degradation machinery (E3 ligase-proteasome system) to tag unwanted proteins for destruction. This catalytic mechanism allows one PROTAC molecule to degrade multiple copies of the target protein, potentially achieving efficacy at lower doses.

Core Analysis & Implications

The approval of vepdegestrant validates PROTAC as a clinically viable platform. For patients with ESR1-mutated breast cancer (where the estrogen receptor remains active despite hormone therapy), degrading the receptor entirely overcomes resistance. The phase 3 data show a doubling of median progression-free survival from 2.1 to 5 months compared to fulvestrant. However, PROTACs have challenges: larger molecular size reduces oral bioavailability, activity can paradoxically decrease at high concentrations, and most current PROTACs rely on only two of the 600+ human E3 ligases, limiting tissue specificity. Resistance may emerge via mutations in the degradation machinery.

Future Outlook / Way Forward

Over 40 PROTAC candidates are in clinical trials targeting more than 200 proteins across cancer, neurodegenerative diseases, inflammatory conditions, and muscle disorders. Future research will focus on expanding the repertoire of recruitable E3 ligases to improve specificity and reduce side effects, optimizing drug-likeness, and overcoming resistance. Long-term safety and real-world effectiveness data will determine how broadly PROTACs can replace or complement existing therapies. For Indian exams, understanding this technology is crucial as it represents a major trend in drug discovery and personalized medicine.

Key Facts at a Glance

Drug NameVepdegestrant

Approval DateMay 1, 2026 (by U.S. FDA)

TechnologyPROTAC (Proteolysis Targeting Chimera)

Target CancerESR1-mutated, ER-positive, HER2-negative advanced breast cancer

DeveloperArvinas & Pfizer

Phase 3 Trial Size624 patients

Progression-Free Survival (ESR1-mutated)5 months (vepdegestrant) vs 2.1 months (fulvestrant)

RouteOral once daily (vs intramuscular injection for fulvestrant)

First PROTAC in Human Trials (2019)Bavdegalutamide (prostate cancer)

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC, Banking

Which companies jointly developed the drug vepdegestrant?

Q2Statement-basedHardUPSC, SSC

Consider the following statements regarding PROTAC technology:

1. PROTACs act as catalysts, degrading target proteins while themselves remaining intact.

2. The first FDA-approved PROTAC drug vepdegestrant targets the estrogen receptor for degradation.

3. PROTACs are small molecules that always have better oral bioavailability than traditional drugs.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, SSC, Banking

In the Phase 3 trial for vepdegestrant, what was the median progression-free survival in patients with ESR1-mutated tumours treated with vepdegestrant?

Q4Application/ImpactMediumUPSC, SSC

Why is the FDA approval of vepdegestrant considered a major shift in cancer therapy?

All 20 MCQs ▸

Read original article from The Hindu

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

Science & TechView Topic MCQs →

Next Caste to be Enumerated in 2027 Census: Pre-test Begins with Open Column for Caste Data

Related Current Affairs

Science & Tech Current Affairs

US FDA Approves First mRNA Flu Shot mFlusiva for Adults 50+ with 26.6% Higher Efficacy

US FDA has approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults aged 50 and older. The vaccine demonstrated 26.6% higher efficacy than standard flu shots in a large late-stage trial. This marks a milestone in mRNA technology beyond COVID-19 and is a key topic for Science & Tech and Health sections.

Science & Tech Current Affairs

CDSCO Approves Qdenga: India's First Dengue Vaccine to be Distributed by Dr Reddy's from 2027

India’s first approved dengue vaccine Qdenga will enter the private market in 2027 via Dr Reddy’s, after CDSCO approval in July 2026. The vaccine is effective against all four serotypes, requires no pre-vaccination screening, and shows 61.2% efficacy against dengue and 84.1% against hospitalization. This is a landmark step in India's fight against dengue.

Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Economy Current Affairs

TN Budget 2026-27: India's First AI City 'Arivagam' & Space Industrial Zone with ₹35,062 Cr MoUs

Tamil Nadu's TVK-led government, in its maiden Budget for 2026-27, announced India's first AI and innovation city 'Arivagam', a Space Industrial Investment Zone in Thoothukudi and Tirunelveli, and signed MoUs worth ₹35,062 crore that could create 14,790 jobs. This signals a major push for technology and industrial growth in the state.

Science & Tech Current Affairs

Indian Railways Launches First LNG-Diesel Dual-Fuel DEMU Train; 40% Diesel Replacement, Rs 23.9 Lakh Annual Savings

Indian Railways has launched its first LNG-diesel dual-fuel DEMU train from Sabarmati, Gujarat, capable of replacing 40% diesel consumption. This follows the hydrogen train launched in July 2026, marking a strategic shift towards alternative fuels to reduce costs and emissions. For exam aspirants, this is a key case study in energy transition and infrastructure modernization.

Science & Tech Current Affairs

IISc SraVaani: India's First Open-Source Speech Recognition Model for 65 Languages

IISc's SPIRE Lab, in collaboration with ARTPARK and Google, has released SraVaani – the first multilingual Indian speech recognition model trained on 65 languages and dialects. It extends ASR to 45 underserved regional languages, potentially benefiting 25 crore people. This marks a major step in inclusive AI for India's linguistic diversity.

Science & Tech Current Affairs

Narayana Health Reports Success in Haplo-Cord Transplant for Thalassaemia & Dual-Target CAR-T for Brain Cancer

Doctors at Narayana Health, West Bengal, have successfully treated a 7-year-old thalassaemia patient using a Haplo-cord transplant and a 62-year-old brain cancer patient with dual-target CAR T-cell therapy. These breakthroughs highlight India's growing capability in advanced cell-based therapies and are landmark achievements in treating previously challenging conditions.

Science & Tech Current Affairs

Merck-Moderna's Personalised mRNA Cancer Vaccine Intismeran Reduces Melanoma Death Risk by 49%

A first-of-its-kind personalised mRNA cancer vaccine (intismeran), developed by Merck and Moderna, combined with Keytruda, has shown a 49% reduction in risk of death from melanoma recurrence and 59% from spread in Phase 3 trials. This marks a breakthrough for cancer vaccines but has limited impact in India due to low melanoma incidence and high cost of immunotherapy.

Start Today's Quiz(20 Qs)

Take Today's Quiz

20 Qs • 5-7 Mins

FDA Approves Vepdegestrant: First PROTAC Drug for Advanced Breast Cancer (May 2026)

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

First PROTAC Approval

Clinical Breakthrough

New Therapeutic Paradigm

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance